2026-08-29T14:55:08Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/172172024-10-31T11:44:56Zcom_20.500.12105_2052com_20.500.12105_2051col_20.500.12105_19613

00925njm 22002777a 4500 dc Shoghli, Mohammadreza author Lokki, A Inkeri author Lääperi, Mitja author Sinisalo, Juha author Lokki, Marja-Liisa author Hilvo, Mika author Jylhä, Antti author Tuomilehto, Jaakko author Laaksonen, Reijo author 2023-12-06 Ceramides and other sphingolipids are implicated in vascular dysfunction and inflammation. They have been suggested as potential biomarkers for hypertension. However, their specific association with hypertension prevalence and onset requires further investigation. This study aimed to identify specific ceramide and phosphatidylcholine species associated with hypertension prevalence and onset. The 2002 FINRISK (Finnish non-communicable risk factor survey) study investigated the association between coronary event risk scores (CERT1 and CERT2) and hypertension using prevalent and new-onset hypertension groups, both consisting of 7722 participants, over a span of 10 years. Ceramide and phosphatidylcholine levels were measured using tandem liquid chromatography-mass spectrometry. Ceramide and phosphatidylcholine ratios, including ceramide (d18:1/18:0), ceramide (d18:1/24:1), phosphatidylcholine (16:0/16:0), and the ratio of ceramide (d18:1/18:0)/(d18:1/16:0), are consistently associated with both prevalence and new-onset hypertension. Ceramide (d18:1/24:0) was also linked to both hypertension measures. Adjusting for covariates, CERT1 and CERT2 showed no-longer-significant associations with hypertension prevalence, but only CERT2 predicted new-onset hypertension. Plasma ceramides and phosphatidylcholines are crucial biomarkers for hypertension, with imbalances potentially contributing to its development. Further research is needed to understand the underlying mechanisms by which ceramides will contribute to the development of hypertension. J Clin Med. 2023 Dec 6;12(24):7524. 10.3390/jcm12247524 2077-0383 Journal of clinical medicine 38137595 http://hdl.handle.net/20.500.12105/17217 Ceramide Phosphatidylcholine CERT1 CERT2 Hypertension Prevalence New-onset hypertension The Novel Ceramide- and Phosphatidylcholine-Based Risk Score for the Prediction of New-Onset of Hypertension